Posted on 6 November 2020
The establishment of a proposed patent linkage registration platform for listed drugs in China is good news for domestic innovative drug applicants, patentees and the generic drug industry. However, in the current draft measures, innovative drug applicants and patentees must actively defend their patents and innovative drugs to avoid possible loss of full exclusivity. In order to protect the legitimate rights and interests of drug innovators and patent holders, as Susie Cheng wrote in the attached article in Chinese newspaper “Medicine Economic News,” published at www.yyjjb.com.cn on November 5, 2020, a balanced approach to an early dispute resolution mechanism should be adopted.
Article for download: 封2.FIT)